{"transactions":[{"id":1517061,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-05-14T20:05:25.000Z","date":"2024-05-13","kind":"sale","planned":true,"acquired":false,"shares":12016,"price":1.26,"value":15140.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on May 12, 2023."},{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023."}],"balance_after":651243,"source":{"system":"sec-edgar","filing":"0001562180-24-004026","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218024004026/primarydocument.xml","form_type":"4"}},{"id":1606387,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-03-01T22:48:25.000Z","date":"2024-02-29","kind":"sale","planned":false,"acquired":false,"shares":5974,"price":1.58,"value":9438.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022."}],"balance_after":663259,"source":{"system":"sec-edgar","filing":"0001562180-24-002022","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218024002022/primarydocument.xml","form_type":"4"}},{"id":1609563,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-02-29T23:03:48.000Z","date":"2024-02-27","kind":"sale","planned":true,"acquired":false,"shares":7411,"price":1.52,"value":11264.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021."},{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023."}],"balance_after":669233,"source":{"system":"sec-edgar","filing":"0001562180-24-001995","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218024001995/primarydocument.xml","form_type":"4"}},{"id":1660934,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2024-02-02T21:10:53.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":224000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":224000,"derivative":{"exercise_price":1.68,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":224000},"source":{"system":"sec-edgar","filing":"0001562180-24-000973","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218024000973/primarydocument.xml","form_type":"4"}},{"id":1660933,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-02-02T21:10:53.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":149300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan.   One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2023 and 1,500 shares of the Issuer's common stock purchased on December 29, 2023, each under the Issuer's  Amended and Restated 2014 Employee Stock Purchase Plan."}],"balance_after":676644,"source":{"system":"sec-edgar","filing":"0001562180-24-000973","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218024000973/primarydocument.xml","form_type":"4"}},{"id":1877719,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2023-05-26T01:01:34.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As previously disclosed, in May 2022, the Reporting Person was granted performance-based options (the \"Options\") pursuant to the Issuer's 2014 Incentive Plan, as amended. The Options vest upon the closing of a significant transaction as defined in the award agreements. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the shares subject to the Option vested on May 24, 2023."}],"balance_after":200000,"derivative":{"exercise_price":0.41,"expiration_date":"2032-05-12","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001562180-23-004504","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023004504/primarydocument.xml","form_type":"4"}},{"id":1877718,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-05-26T01:01:34.000Z","date":"2023-05-25","kind":"sale","planned":false,"acquired":false,"shares":63186,"price":1.2229,"value":77270.1594,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of all of the PSUs."}],"balance_after":524344,"source":{"system":"sec-edgar","filing":"0001562180-23-004504","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023004504/primarydocument.xml","form_type":"4"}},{"id":1877717,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-05-26T01:01:34.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As previously disclosed, in May 2022, the Reporting Person was granted performance-based restricted stock units (\"PSUs\") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest upon the closing of a significant transaction as defined in the award agreement. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the PSUs vested on May 24, 2023"}],"balance_after":587530,"source":{"system":"sec-edgar","filing":"0001562180-23-004504","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023004504/primarydocument.xml","form_type":"4"}},{"id":1891059,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-05-16T20:10:52.000Z","date":"2023-05-12","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":387530,"source":{"system":"sec-edgar","filing":"0001562180-23-004169","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023004169/primarydocument.xml","form_type":"4"}},{"id":1971971,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-03-03T13:01:24.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":1088,"price":0.8775,"value":954.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021."}],"balance_after":287530,"source":{"system":"sec-edgar","filing":"0001562180-23-002200","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023002200/primarydocument.xml","form_type":"4"}},{"id":1971970,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-03-03T13:01:24.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":6613,"price":0.8775,"value":5802.9075,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020."}],"balance_after":288618,"source":{"system":"sec-edgar","filing":"0001562180-23-002200","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023002200/primarydocument.xml","form_type":"4"}},{"id":1971969,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-03-03T13:01:24.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":5333,"price":0.8775,"value":4679.7075,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022."}],"balance_after":295231,"source":{"system":"sec-edgar","filing":"0001562180-23-002200","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023002200/primarydocument.xml","form_type":"4"}},{"id":1983106,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-03-01T21:05:39.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":6677,"price":0.8132,"value":5429.7364,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,500 shares of the Issuers common stock purchased on June 30, 2022, and 1,500 shares of the Issuers common stock purchased on December 30, 2022, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan."}],"balance_after":300564,"source":{"system":"sec-edgar","filing":"0001562180-23-002037","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023002037/primarydocument.xml","form_type":"4"}},{"id":2359619,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2022-03-03T02:10:24.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":200000,"derivative":{"exercise_price":2.16,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001562180-22-002161","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218022002161/primarydocument.xml","form_type":"4"}},{"id":2359618,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-03-03T02:10:24.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":1078,"price":2.1707,"value":2340.0146,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes 1,500 shares of the Issuers common stock purchased on June 30, 2021 and 1,500 shares of the Issuers common stock purchased on December 31, 2021, each under the Issuers 2014 Amended and Restated Employee Stock Purchase Plan."}],"balance_after":304241,"source":{"system":"sec-edgar","filing":"0001562180-22-002161","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218022002161/primarydocument.xml","form_type":"4"}},{"id":2359617,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-03-03T02:10:24.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":6556,"price":2.1707,"value":14231.1092,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020."}],"balance_after":302319,"source":{"system":"sec-edgar","filing":"0001562180-22-002161","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218022002161/primarydocument.xml","form_type":"4"}},{"id":2359616,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-03-03T02:10:24.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":6873,"price":2.1707,"value":14919.2211,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019."}],"balance_after":308875,"source":{"system":"sec-edgar","filing":"0001562180-22-002161","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218022002161/primarydocument.xml","form_type":"4"}},{"id":2359615,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-03-03T02:10:24.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One-third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":315748,"source":{"system":"sec-edgar","filing":"0001562180-22-002161","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218022002161/primarydocument.xml","form_type":"4"}},{"id":2359614,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-03-03T02:10:24.000Z","date":"2022-02-28","kind":"sale","acquired":false,"shares":6555,"price":2.1548,"value":14124.714,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021."}],"balance_after":265748,"source":{"system":"sec-edgar","filing":"0001562180-22-002161","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218022002161/primarydocument.xml","form_type":"4"}},{"id":2763444,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-04-02T00:33:54.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":1060,"price":3.4,"value":3604.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021."}],"balance_after":272303,"source":{"system":"sec-edgar","filing":"0001562180-21-002542","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218021002542/primarydocument.xml","form_type":"4"}},{"id":2778765,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-03-18T23:18:22.000Z","date":"2021-03-16","kind":"grant","acquired":true,"shares":10192,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As previously disclosed, in February 2020, the Reporting Person was granted performance-based restricted stock unit awards (\"PSUs\") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest in connection with the achievement of specified commercial and regulatory milestones. On February 25, 2021, the Company reported its financial results for the year ended December 31, 2020.  Subsequently, in accordance with the terms of the grant, the Issuer's Compensation Committee certified the achievement of a commercial milestone and, as a result, one third of the reported PSUs will vest on each of March 31, 2021, February 28, 2022 and February 28, 2023, subject to the Reporting Person's continued service with the Issuer on each vesting date."}],"balance_after":273363,"source":{"system":"sec-edgar","filing":"0001562180-21-002356","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218021002356/primarydocument.xml","form_type":"4"}},{"id":2818972,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-03-02T21:08:27.000Z","date":"2021-02-26","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":110000,"derivative":{"exercise_price":3.46,"expiration_date":"2031-02-26","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001562180-21-001785","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218021001785/primarydocument.xml","form_type":"4"}},{"id":2818971,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-03-02T21:08:27.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":7976,"price":3.3961,"value":27087.2936,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019."}],"balance_after":263171,"source":{"system":"sec-edgar","filing":"0001562180-21-001785","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218021001785/primarydocument.xml","form_type":"4"}},{"id":2818970,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-03-02T21:08:27.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":6309,"price":3.3961,"value":21425.9949,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020."}],"balance_after":271147,"source":{"system":"sec-edgar","filing":"0001562180-21-001785","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218021001785/primarydocument.xml","form_type":"4"}},{"id":2818969,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-03-02T21:08:27.000Z","date":"2021-02-26","kind":"grant","acquired":true,"shares":62000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2020 and 1,200 shares of the Issuer's common stock purchased on December 31, 2020, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan."}],"balance_after":277456,"source":{"system":"sec-edgar","filing":"0001562180-21-001785","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218021001785/primarydocument.xml","form_type":"4"}},{"id":3237409,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2020-03-03T00:28:27.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter."}],"balance_after":105000,"derivative":{"exercise_price":8.87,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001562180-20-001936","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218020001936/primarydocument.xml","form_type":"4"}},{"id":3237408,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-03-03T00:28:27.000Z","date":"2020-02-28","kind":"sale","acquired":false,"shares":7050,"price":8.7,"value":61335.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019."}],"balance_after":212756,"source":{"system":"sec-edgar","filing":"0001562180-20-001936","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218020001936/primarydocument.xml","form_type":"4"}},{"id":3237407,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-03-03T00:28:27.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":62000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,500 shares of the Issuer's common stock purchased on June 28, 2019 and 1,500 shares of the Issuer's common stock purchased on December 31, 2019, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan."}],"balance_after":219806,"source":{"system":"sec-edgar","filing":"0001562180-20-001936","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218020001936/primarydocument.xml","form_type":"4"}},{"id":3556400,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CLO & Secretary"}}],"security":"Common Stock","published_at":"2019-04-12T20:00:41.000Z","date":"2019-04-11","kind":"disposition_to_issuer","acquired":false,"shares":11929,"price":7.7,"value":91853.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The proceeds from the disposition of these shares are to be used by the reporting person to cover tax liabilities associated with previously vested restricted stock units."}],"balance_after":154806,"source":{"system":"sec-edgar","filing":"0000899243-19-010589","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000089924319010589/doc4.xml","form_type":"4"}},{"id":3610806,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CLO & Secretary"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2019-03-05T21:06:17.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter."}],"balance_after":100000,"derivative":{"exercise_price":7.28,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001562180-19-001676","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218019001676/primarydocument.xml","form_type":"4"}},{"id":3610805,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CLO & Secretary"}}],"security":"Common Stock","published_at":"2019-03-05T21:06:17.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended.  One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 451 shares of the Issuer's common stock purchased under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2018."}],"balance_after":166735,"source":{"system":"sec-edgar","filing":"0001562180-19-001676","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218019001676/primarydocument.xml","form_type":"4"}},{"id":3731824,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel, Sec."}}],"security":"Common Stock","published_at":"2018-12-13T13:15:27.000Z","date":"2018-12-12","kind":"tax_withholding","acquired":false,"shares":20175,"price":8.94,"value":180364.5,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,381 shares acquired under the Akebia Therapeutics, Inc. stock purchase plan on June 29, 2018."}],"balance_after":101284,"source":{"system":"sec-edgar","filing":"0000899243-18-030794","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000089924318030794/doc4.xml","form_type":"4"}},{"id":4019292,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel, Sec."}}],"security":"Employee Stock Option (Right to buy)","published_at":"2018-03-02T21:15:40.000Z","date":"2018-02-28","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options were granted by the Issuer pursuant to its 2014 Incentive Plan.  25% of the shares underlying this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter."}],"balance_after":25000,"derivative":{"exercise_price":14.3,"expiration_date":"2028-02-28","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-18-001385","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218018001385/primarydocument.xml","form_type":"4"}},{"id":4019291,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel, Sec."}}],"security":"Common Stock","published_at":"2018-03-02T21:15:40.000Z","date":"2018-02-28","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan. One hundred percent of the restricted stock units will vest on the third anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total amount of beneficial securities owned includes 774 shares of stock purchased on December 31, 2017 at $12.39 per share in connection with the Issuer's Employee Stock Purchase Plan."}],"balance_after":120078,"source":{"system":"sec-edgar","filing":"0001562180-18-001385","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218018001385/primarydocument.xml","form_type":"4"}},{"id":4191760,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel, Sec."}}],"security":"Common Stock","published_at":"2017-10-04T20:21:02.000Z","date":"2017-10-02","kind":"sale","acquired":false,"shares":6250,"price":19.95,"value":124687.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares sold by Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2017."}],"balance_after":101804,"source":{"system":"sec-edgar","filing":"0001562180-17-003206","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218017003206/primarydocument.xml","form_type":"4"}},{"id":4191759,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel, Sec."}}],"security":"Common Stock","published_at":"2017-10-04T20:21:02.000Z","date":"2017-10-02","kind":"sale","acquired":false,"shares":1553,"price":19.64,"value":30500.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold by Reporting Person pursuant to a Rule 10b5-1 trading plan to pay taxes in connection with the vesting of restricted stock pursuant to the December 23, 2013 restricted stock award."}],"balance_after":108054,"source":{"system":"sec-edgar","filing":"0001562180-17-003206","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218017003206/primarydocument.xml","form_type":"4"}},{"id":4261486,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel, Sec."}}],"security":"Common Stock","published_at":"2017-07-06T16:24:47.000Z","date":"2017-07-03","kind":"sale","acquired":false,"shares":1554,"price":14.2577,"value":22156.4658,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through October 1, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.11 to $14.41, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The total amount of beneficial securities includes 1,305 shares of stock purchased on June 30, 2017 at $8.92 per share in connection with the Issuer's Employee Stock Purchase Plan."}],"balance_after":109607,"source":{"system":"sec-edgar","filing":"0001562180-17-002434","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218017002434/primarydocument.xml","form_type":"4"}},{"id":4359989,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel, Sec."}}],"security":"Common Stock","published_at":"2017-04-04T20:01:15.000Z","date":"2017-04-03","kind":"sale","acquired":false,"shares":1556,"price":9.1775,"value":14280.19,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through October 1, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.15 to $9.24, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":109856,"source":{"system":"sec-edgar","filing":"0001562180-17-001429","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218017001429/primarydocument.xml","form_type":"4"}},{"id":4427191,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel, Sec."}}],"security":"Stock Option (Right to buy)","published_at":"2017-02-23T21:02:16.000Z","date":"2017-02-21","kind":"grant","acquired":true,"shares":45000,"price":10.14,"value":456300.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares underlying this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter."}],"balance_after":45000,"derivative":{"exercise_price":0,"expiration_date":"2027-02-21","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001562180-17-000880","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218017000880/primarydocument.xml","form_type":"4"}},{"id":4427190,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel, Sec."}}],"security":"Common Stock","published_at":"2017-02-23T21:02:16.000Z","date":"2017-02-21","kind":"grant","acquired":true,"shares":28500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan. One hundred percent of the restricted stock units will vest on the third anniversary of the grant date."}],"balance_after":111412,"source":{"system":"sec-edgar","filing":"0001562180-17-000880","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218017000880/primarydocument.xml","form_type":"4"}},{"id":4507257,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel, Sec."}}],"security":"Common Stock","published_at":"2017-01-03T21:01:51.000Z","date":"2017-01-01","kind":"sale","acquired":false,"shares":1810,"price":10.4906,"value":18987.986,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through October 1, 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total amount of beneficial securities includes 807 shares of stock purchased on December 30, 2016 at $6.48 per share in connection with the Issuer's Employee Stock Purchase Plan."}],"balance_after":82912,"source":{"system":"sec-edgar","filing":"0001562180-17-000080","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218017000080/primarydocument.xml","form_type":"4"}},{"id":4586005,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":91066,"kind":"person","name":"Hadas Nicole R.","position":1,"cik":"0001602396","reported_name":"Hadas Nicole R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel, Sec."}}],"security":"Common Stock","published_at":"2016-10-04T20:12:12.000Z","date":"2016-10-01","kind":"sale","acquired":false,"shares":1556,"price":8.9548,"value":13933.6688,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through December 2, 2017."}],"balance_after":83915,"source":{"system":"sec-edgar","filing":"0001562180-16-003206","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218016003206/primarydocument.xml","form_type":"4"}}]}